A method for alleviating at least one of the clinical symptoms of a person suffering from AIDS or ARC, said method comprising administering to said person an effective dosage amount of YG Product, and said symptoms comprising decrease in percentage of {TAIL ~ T helper cells}, weight loss, diarrhea, tissue breakdown characterized by increase in serum level of uric acid or {HEAD ~ creatine phosphokinase}, and candidiasis, said YG Product being YG; methylated, acetylated, amidified, esterified, or alcoholated YG; or a pharmaceutically acceptable salt of any of the foregoing 
A method for alleviating at least one of the clinical symptoms of a person suffering from AIDS or ARC , said method comprising administering to said person an effective dosage amount of YG Product , and said symptoms comprising decrease in percentage of { TAIL ~ T helper cells } , weight loss , diarrhea , tissue breakdown characterized by increase in serum level of uric acid or { HEAD ~ creatine phosphokinase } , and candidiasis , said YG Product being YG ; methylated , acetylated , amidified , esterified , or alcoholated YG ; or a pharmaceutically acceptable salt of any of the foregoing
OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH TAIL TAIL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH